Study of circulating biomarkers in nasopharyngeal cancer

By Sawsan Feki, Amin Chakroun, Ismail Hachicha

To date, there is no reliable biomarker validated in the exploration of nasopharyngeal cancer (NPC). To assess the value of 2 markers: Cyfra 21-1, a fragment of cytokeratin 19, and β2Microglobulin, a cell membrane protein, in CNP in southern Tunisia, we included 103 individuals: 50 patients with a primary diagnosis of CNP and 53 healthy controls. CNP patients were classified according to the American Joint Committee on Cancer (AJCC 2010) and the 8th edition TNM (UICC 2017). 40/50 (80%) of CNP patients were positive for at least one of the two markers. The mean serum level of Cyfra 21-1 was significantly higher in patients than in controls. None of the controls had an elevated level of this marker. The sensitivity of Cyfra 21-1 in CNP (66%) reached 100% for patients =III). Regarding β2M, 56% of patients had an elevated level of the marker. In conclusion, Cyfra 21-1 could be a reliable biomarker for the diagnosis and prognosis of NPC. Combining this marker with β2M could improve diagnostic sensitivity.

• Format: Paperback
• Language: English
• ISBN: 620718081X
• ISBN13: 9786207180813
• Release Date: February 2024
• Publisher: Our Knowledge Publishing
• Length: 52 Pages
• Weight: 0.20 lbs.
• Dimensions: 0.1" x 6.0" x 9.0"